Synthesis of Thrombotic Disease Intermediates via Azide-Free Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing process for producing Compound (VI-I), which exhibits activated blood coagulation factor Xa inhibitory action and is used for thrombotic diseases, is disadvantageous due to the use of highly toxic sodium azide, requires ultra-low-temperature conditions, employs environmentally unfriendly solvents like dichloromethane, and has low production yield.
Innovation Solution
A process involving treatment of Compound (I) with aqueous ammonia and dialkyl dicarbonate, followed by reaction with Compound (III) in the presence of a base, and subsequent hydrogenolysis under normal pressure conditions using a metallic catalyst, to produce Compound (VI-I) with high yield and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If highly toxic sodium azide is used to produce Compound (II) from Compound (I), then the production process can proceed, but the process becomes unsafe and requires special handling facilities
Solution Approach 1:
The patent extracts and removes the highly toxic sodium azide from the synthesis pathway. Instead of using sodium azide to produce Compound (II), the invention employs a safer alternative reagent system that eliminates the toxic substance while maintaining the ability to produce the desired intermediate compound.
Solution Approach 2:
The patent introduces an intermediary substance or reaction pathway that replaces sodium azide. This intermediary approach allows the synthesis to proceed through a different mechanism that avoids the toxic reagent while still achieving the same chemical transformation goal.
2Object-affected harmful factors
If azide must be subjected to hydrogenolysis to remove toxic azide, then safety is improved, but additional process steps and equipment are required
Solution Approach 1:
The patent extracts the problematic azide functionality from the synthesis pathway entirely. By using an alternative reagent that does not require hydrogenolysis for removal, the invention eliminates the need for additional equipment such as hydrogenation reactors and simplifies the overall process flow.
Solution Approach 2:
The patent enables a continuous synthesis process where the desired compound is produced directly without interruption for azide removal steps. The alternative reagent system allows the reaction to proceed continuously through all stages without requiring intermediate processing steps for toxic substance elimination.
3Ease of manufacture
If dichloromethane is used as solvent in the production of Compound (IV), then the reaction can proceed effectively, but the process becomes environmentally unfriendly
Solution Approach 1:
The patent changes the solvent parameter from dichloromethane to an environmentally friendly alternative. This parameter substitution maintains the necessary reaction conditions and effectiveness while eliminating the environmental harm associated with halogenated solvents, aligning the process with green chemistry principles.
4Manufacturing precision
If ultra-low-temperature conditions (-30 to -78°C) are employed, then the reaction selectivity is improved, but the process becomes industrially disadvantageous due to equipment requirements
Solution Approach 1:
The patent changes the temperature parameter from ultra-low conditions (-30 to -78°C) to a more moderate temperature range suitable for industrial processing. This parameter modification maintains adequate reaction selectivity while eliminating the need for specialized cryogenic equipment, thereby improving industrial scalability and reducing capital investment requirements.
5Ease of manufacture
If the existing process is used to produce Compound (V), then the reaction can proceed, but the production yield is considerably low (about 30 to 40%)
Solution Approach 1:
The patent optimizes reaction parameters including temperature, solvent type, and reagent ratios to significantly improve the yield of Compound (V). By adjusting these parameters within a revised synthetic pathway, the invention achieves substantially higher productivity while maintaining process feasibility and simplifying the overall manufacturing approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process reduces the use of toxic reagents, eliminates halogen-base solvents, and significantly enhances production yield, making it industrially applicable and environmentally friendly.
Implementation Method 1
treating Compound (I) with aqueous ammonia or a similar substance in a solvent results in regio-specific nucleophilic attack of amine
Implementation Method 2
Compound (II) is produced through protection of the amine with dialkyl dicarbonate
Implementation Method 3
reduction of Compound (V) proceeds through hydrogenolysis under normal pressure conditions in the presence of a hydrogen source and a metallic catalyst
Data Source
AI summary
The invention is directed to a process for producing intermediates of a compound which exhibits an activated blood coagulation factor Xa inhibitory action and which is a useful preventive and a therapeutic agent for thrombotic diseases. The intermediate production process is represented by the following reaction scheme.